Jardiance Tablet, Film Coated
Product Images NDC 50090-6457

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 50090-6457). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Jardiance 01)

Chemical structure of Empagliflozin, the active ingredient in Jardiance 25 mg oral film-coated tablets. The structure shows multiple rings and functional groups including hydroxyl, ether, and chlorinated aromatic components.*

FDA Label Image

Figure 1 (Jardiance 02)

A forest plot chart showing the geometric mean ratio with 90% confidence intervals for the area under the curve (AUC) and maximum concentration (Cmax) comparing various antidiabetic and other drugs relative to empagliflozin alone. The chart displays the change relative to empagliflozin on the x-axis, ranging from 50 to 200, with drugs listed on the y-axis by name, dose, and frequency.*

FDA Label Image

Figure 2 (Jardiance 03)

A forest plot chart illustrating the geometric mean ratios with 90% confidence intervals for the area under the curve (AUC) and maximum concentration (Cmax) of various drugs, including antidiabetic agents, oral contraceptives, and others. The x-axis represents the ratio range from 50 to 150, showing comparative pharmacokinetic data.*

FDA Label Image

Figure 3 (Jardiance 04)

A line graph showing mean change in HbA1c (%) from baseline over 24 weeks for placebo and empagliflozin 10 mg and 25 mg groups. The x-axis represents time in weeks, and the y-axis shows mean change from baseline in HbA1c (%) with values ranging from -0.75 to 0.25. Data includes sample sizes and error bars for week 24 results.*

FDA Label Image

Figure 4 (Jardiance 05)

A line graph comparing mean percentage changes in HbA1c from baseline over 52 weeks between two treatment groups: Glimepiride plus Metformin (N=700) and Empagliflozin 25 mg plus Metformin (N=693). The graph plots time in weeks on the x-axis and HbA1c mean change percentage on the y-axis, illustrating differences in glycemic control between the treatments with error bars for week 52.*

FDA Label Image

Figure 5 (Jardiance 06)

A line graph comparing the percentage of patients with events over 48 months between placebo and all empagliflozin treatments. The y-axis represents patients with events as a percentage, and the x-axis shows time in months. Data below the graph shows subjects at risk for each group at various time points.*

FDA Label Image

Figure 6 (Jardiance 07)

A line graph comparing the percentage of patients with an event over 48 months between placebo and empagliflozin treatment groups. The y-axis shows patients with event (%) from 0 to 20, while the x-axis displays months from 0 to 48. Data for subjects at risk over time is provided below the graph.*

FDA Label Image

Qr Code (Jardiance 08)

FDA Label Image

Figure 7 (Jardiance 08a)

A line graph comparing estimated cumulative incidence function percentages over days since randomization between placebo and Empagliflozin 10 mg groups. The X-axis shows days since randomization up to 810 days, and the Y-axis shows cumulative incidence percentage up to 35%. Two lines represent placebo and Empagliflozin 10 mg, showing lower incidence in the Empagliflozin group. Patient counts at risk are listed below the X-axis for each group at various time points.*

FDA Label Image

Figure 8 (Jardiance 08b)

A line graph comparing the mean number of events over time between two groups: patients receiving Empagliflozin 10 mg and a placebo. The x-axis represents days since randomization, and the y-axis shows the mean number of events. The graph includes patient counts at risk for each group at various time points up to 810 days.*

FDA Label Image

Figure 9 (Jardiance 08c)

A forest plot representing hazard ratios with 95% confidence intervals comparing Empagliflozin 10 mg versus placebo across various subgroups, including diabetes status, age, sex, race, BMI, eGFR, NYHA class, heart failure physiology, and baseline medication use. The plot visually indicates the relative event rates favoring Empagliflozin or placebo.*

FDA Label Image

Figure 10 (Jardiance 08d)

A Kaplan-Meier curve chart showing estimated cumulative incidence function percentages over days since randomization for two groups: placebo and Empagliflozin 10 mg. The chart includes a comparison of hazard ratio (HR 0.79) with 95% confidence interval and p-value, and a table of patients at risk over time for each group.*

FDA Label Image

Figure 11 (Jardiance 08e)

A Kaplan-Meier curve comparing mean number of events over days since randomization for placebo and Empagliflozin 10 mg groups. The graph shows lower event occurrence in the Empagliflozin group versus placebo, with hazard ratio and confidence interval noted. Patient counts at risk are displayed over time for both groups.*

FDA Label Image

Figure 12 (Jardiance 08f)

A forest plot chart displaying hazard ratios with 95% confidence intervals comparing Empagliflozin 10 mg versus placebo across various patient subgroups, including diabetes status, age, sex, race, BMI, eGFR levels, NYHA class, LVEF, NT-proBNP levels, and baseline use of MRA. The chart indicates the relative treatment effect and confidence intervals for each subgroup.*

FDA Label Image

Label Image (Lbl500906457)

Label for JARDIANCE 25 mg film-coated tablets containing empagliflozin, distributed by A-S Medication Solutions. The label indicates storage at 68 to 77 degrees Fahrenheit and packaging of 90 tablets. Includes product and lot numbers and a dosage instruction to see the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.